IXICO links up with Microsoft to enhance AI platform

0
82
  • IXICO expects revenues to recover as Covid disruption eases
  • IXICO contract win is “strong endorsement” and supports growth strategy, says broker
  • Ixico set to return to double digit growth in 2022 as impact of Covid-19 on drug trials eases
Medical scanner

Quick facts: IXICO PLC

Follow

View company profile

IXICO is a leading neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights.

Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

06 Aug 2021

(, , ) said it expects to see double-digit revenue growth again in its current fiscal year as the impact of Covid-19 on drug trials eases and activity picks up again.

Giulio Cerroni, chief executive, said: “Having grown rapidly over recent years, we acknowledge that we are not immune to the industry-wide impacts of COVID-19 and the unexpected developments on our largest client’s trials.

“As clinical trials delayed due to the COVID-19 crisis are initiated and by ensuring commercial execution of our growing pipeline, we anticipate returning to a double-digit revenue growth trajectory as our 2022 financial year progresses.”

The neuroscience data specialist flagged earlier in the year that one of its largest customers had halted a phase III trial of a treatment for Huntington’s disease and that the general disruption to other trials caused by Covid-19 was also having an effect.

Read more

25 May 2021

() has reported higher revenues and earnings in its first half as the group highlighted continued growth in its order book despite the effects of the Coronavirus (COVID-19) pandemic.

In its results for the six months ended March 31, the neuroscience-focused data analytics firm reported earnings (EBITDA) of GBP0.9mln, up from GBP0.7mln a year ago, while revenues rose to GBP4.9mln to GBP4.6mln.

Read more

20 May 2021

() has been awarded an expansion contract by a current biopharmaceutical client to support the company’s Phase II Alzheimer’s disease clinical trial.

The clinical trial will investigate the efficacy, safety and tolerability of an anti-Tau antibody treatment for individuals with prodromal and mild Alzheimer’s disease.

Read more

28 Apr 2021

‘s (LON:IXI, ) latest neuroimaging contract is “a strong endorsement” of the company’s differentiated platform, said broker Shore Capital, reiterating its ‘buy’ recommendation on the shares.

The expansion into a new therapeutic area is supportive of the organic growth strategy to broaden IXICO’s footprint and deepen its expertise, the broker added.

Shore Cap also highlighted a “healthy” order book of GBP19mln and strong cash position of GBP7mln as at the end of March.

Read more

11 Aug 2021

(, , ) () CFO Grant Nash joins Proactive London’s Katie Pilbeam about returning to double-digit revenue growth again in 2022 as the impact of Covid-19 on drug trials eases and activity picks up again.

Nash explains that having enjoyed exceptional growth over recent years, industry-wide impacts of COVID-19 and the unexpected developments from their largest client’s trials have had an impact but the market itself has not changed.

As a result, Ixico now expects to report revenues of GBP8.7mln in the year to end September 2021 and underlying profits [EBITDA] of GBP1.2mln compared to revenues of GBP9.5mln and underlying profits of GBP1.3mln in 2020.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Ixico set to return to double digit growth in 2022 as impact of Covid-19 on…

IXICO PLC (AIM:IXI, FRA:PYPB, OTC:PHYOF) (LON:IXI) CFO Grant Nash joins Proactive London’s Katie Pilbeam about returning to double-digit revenue growth again in 2022 as the impact of Covid-19 on drug trials eases and activity picks up again.

Nash explains that having enjoyed exceptional…

9 hours, 43 minutes ago

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here